Display Settings:

Format

Send to:

Choose Destination

    Oncogene. 2006 Sep 25;25(43):5825-31.

    Clinical management of BRCA1 and BRCA2 mutation carriers.

    Domchek SM, Weber BL.

    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. susan.domchek@uphs.upenn.edu

    The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.

    PMID: 16998496 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read